Cytokinetics(US:CYTK) Newsfile·2025-11-12 02:10Core Viewpoint - Rosen Law Firm is encouraging investors of Cytokinetics, Inc. to secure legal counsel before the November 17, 2025 deadline for a securities class action lawsuit related to the company's stock performance during a specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is defined as December 27, 2023, to May 6, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by November 17, 2025, to represent other class members in the litigation [3][6]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process, leading to investor damages when the true information became public [5].